Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Ms. Catharina Jz Johansson

Market Cap

168.59 Million SEK

Sector

Healthcare

Website

https://abliva.com

Last Update

2/22/2024, 12:00:00 PM

Description

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases.

Read More

Overview

Value

2

Growth

64

Health

19

Management

59

Analyst Opinion

51

Total

39

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • Altman-Z score suggests a risk of bankruptcy
  • Poor overall financial health
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Accounting anomalies: Growing revenues without a corresponding growth in cash flows.
  • Dividend could be at risk

Market Peers

ABLI.ST

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-86.40%

Revenue Growth (5 Year Average)

29.52%

Ratings Consensus

Neutral

Share Buybacks

-62.18%

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

2

  • Estimated intrinsic-value of 20.43 undefined SEK is lower than current price ( 159.60 undefined SEK)
  • Free-cashflow-yeild of -5.73% is worse than the market average (4.7%)
  • Margin-of-safety of -86.40% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0.2 SEK

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-5.73%

PE/Earnings Growth

N/A

Price/Book

2.24x

Growth

Growth Score

64

  • 5 Year Average Revenue growth of 29.52% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 20.96% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Free Cashflow growth of -1.38% is lower than the market average (12.35%)

Revenue Growth

29.52%

Earnings Growth

20.96%

Cashflow Growth

-1.38%

Health

Health Score

19

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Debt repayments significantly impact cashflow

Altman Z Score

0.00

Piostroski Score

2.00

Debt/Equity

0.00x

Current Assets/Liabilities

1.39x

Free Cashflow/Total Debt

0.00x

Debt/Capital

0.00x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

59

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -154.84% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -839.57% is lower than the market average (15%)

Average Buybacks/Dilution

-62.18%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

67.65%

Return On Assets

-591.63%

Return On Capital Employed

-154.84%

Return On Equity

-839.57%

Return On Free Cashflow

N/A

Return On Investments

-2660.71%

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

51

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Abliva AB (publ)

Currency

SEK

Beta

1.199176

Vol Avg

2209196

Ceo

Ms. Catharina Jz Johansson

Cik

Cusip

Exchange

Stockholm Stock Exchange

Full Time Employees

8

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2008-10-03

Address

Medicon Village

City

Lund

State

Country

SE

Zip

223 81

Phone

46 4 62 75 62 20

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies